Remove 2018 Remove IT Remove Provider Remove Utilities
article thumbnail

Exploring Primary Care Provider eConsult Utilization Trends [Health care services, delivery, and financing]

Annals of Family Medicine

Context: The University of Colorado School of Medicine (CUSOM) launched their eConsult program in 2018. Objective: To determine how primary care providers (PCP) utilize the eConsult platform. Study Design and Analysis: This retrospective analysis of program data spans from 2018 through 2023.

Utilities 130
article thumbnail

Dashboard of Advancement and Success for Health Services Research (DASH) 2.0 [Research capacity building]

Annals of Family Medicine

Weekly meetings consist of a review of projects using the Dashboard of Advancement and Success for Health Services Research(DASH), which has been actively in use since its creation in 2018. The DASH is now housed on SharePoint and is utilized weekly to document project progress and share opportunities of funding or professional development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Mental Health & SUD Bias Impact ED Physical Care

Physician's Weekly

This study uncovered negative and positive provider, treatment, and system-related factors that contribute to these patients’ experiences and offered recommendations for improving care experiences.” Provide printed “What to Expect” one‑pagers at registration to align patient expectations with ED capabilities. Clarify ED scope.

article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

FDA Law

In fact, in 2018, FDA emphasized that leveraging the use of RWD and RWE in regulatory decision-making is “a top strategic priority for the FDA.” Rather than looking at how RWD/RWE provide meaningful information on safety and effectiveness, reviewers often focus on perceived gaps. percent of examples.

Medical 111
article thumbnail

FDA’s Third Party Review Program is Ready for the Next Pandemic, not the LDT Final Rule

FDA Law

The final guidance appears not to make any meaningful changes that are actually likely to support or incentivize its increased utilization, which is disappointing, although not unsurprising. The guidance also addresses FDAs obligation to provide considerations on third party compensation, information sharing, and conflicts of interest.

article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Tsai has seen race-based medicine play out in clinical practice 10:45 What role should race play in making clinical decisions? 13:16 Status of the current conversation on removing race from eGFR calculators: why is it so contentious? Poet Marge Piercy has written, “The work of the world is as common as mud.”

Clinic 52
article thumbnail

Goodbye NSURE, Hello ACNU! FDA Issues Long-Awaited Proposed Rule to Bring OTC Drugs with a Little Something Extra to Market

FDA Law

The first was to develop labeling beyond the DFL and the second was to propose “additional conditions that a consumer must fulfill” with the examples self-selection tests utilizing a mobile app or a requirement for the consumer to affirm they have watched a video or read text about use of the drug. This brings us back to the ANDAs.